Craig Williams Takes Helm at Apriori Bio as CEO
Portfolio - People | Nov 13, 2024 | Flagship Pioneering Inc
Flagship Pioneering, a bioplatform innovation company, has announced the promotion of Craig Williams to the role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Apriori Bio. Apriori Bio, a biotechnology company focused on creating vaccines offering variant-resilient protection against evolving viruses, has made significant advances, including a collaboration with CEPI and developing a vaccine pipeline. Williams, who joined as an Operating Partner and President of Apriori Bio in 2023, has a strong background in vaccine development from his time at GSK and ViiV Healthcare, where he helped launch over 15 vaccines globally. Noubar Afeyan, Founder and CEO of Flagship Pioneering, and Lovisa Afzelius, Co-Founder and Chair of Apriori, express confidence in Williams' leadership. Under his guidance, Apriori aims to strengthen its position in next-generation vaccine design. As CEO, Williams is focused on developing innovative vaccines and leveraging Apriori's Octavia platform to advance health solutions and inform public policy.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- United States – Both Flagship Pioneering and Apriori Bio are based in Cambridge, Massachusetts, a significant hub for biotechnology and pharmaceuticals.
Industry
- Biotechnology – The article revolves around Apriori Bio, a biotechnology company focused on developing advanced vaccines, reflecting the industry's push towards innovative health solutions.
- Pharmaceuticals – Given Craig Williams' background with GSK and role in commercialization of vaccines, the pharmaceutical industry is relevant to the development and distribution of vaccines.
- Venture Capital – Flagship Pioneering operates as a venture creation company investing and building bioplatforms, aligning with venture capital initiatives.
Financials
- $14 billion – The value of assets under management reported by Flagship Pioneering as of its latest capital raise in July 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Craig Williams | CEO-Partner and Chief Executive Officer | People | Recently promoted to CEO-Partner at Flagship Pioneering and CEO of Apriori Bio, Williams has a strong track record in vaccine development and commercialization. |
| Flagship Pioneering | Owner and Investor | Company | A bioplatform innovation company that invents and builds scientific ventures, including Apriori Bio. |
| Apriori Bio | Target Company | Company | Biotechnology company focused on providing variant-resilient vaccines against evolving viruses. |
| CEPI | Collaborator | Company | A collaborator with Apriori Bio in developing the next generation of vaccines. |
| Noubar Afeyan | Founder and CEO | People | Founder and CEO of Flagship Pioneering, expressing confidence in Williams' leadership. |
| Lovisa Afzelius | Co-Founder and Chair | People | Co-Founder and Chair of Apriori Bio and General Partner at Flagship Pioneering. |